Cassava Sciences to Present at the 2023 H.C. Wainwright Investor Conference

Rhea-AI Summary

Cassava Sciences, focused on Alzheimer’s disease, announced that Remi Barbier, President & CEO, will present at the 2023 H.C. Wainwright BioConnect Investor Conference in New York on May 2nd at 3 PM Eastern time. This event provides a platform for the company to engage with institutional investors through one-on-one meetings. Investors can access the live webcast here and the archived replay here. Cassava Sciences aims to innovate treatments for neurodegenerative diseases by stabilizing key brain proteins, although none of their products have been approved by regulatory authorities.

News Market Reaction – SAVA

-1.42%

-1.42% Session move

In the trading session that priced this news, SAVA declined 1.42%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

AUSTIN, Texas, April 26, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that Remi Barbier, President & Chief Executive Officer, has been invited to present at the 2023 H.C. Wainwright BioConnect Investor Conference in New York. In addition, management will be available for one-on-one meetings with institutional investors who are registered to attend this conference.

When: Tuesday, May 2^nd at 3pm Eastern time

Live Webcast: https://journey.ct.events/view/f51ce8f9-51a5-45e8-891b-e3623ecb6305

Archived Replay: https://www.CassavaSciences.com/company-presentations

About Cassava Sciences, Inc.
Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer’s disease. Our novel science is based on stabilizing—but not removing—a critical protein in the brain. Our product candidates have not been approved by any regulatory authority, and their safety, efficacy or other desirable attributes have not been established. For more information, please visit: https://www.CassavaSciences.com.

For More Information Contact:
Eric Schoen, Chief Financial Officer
(512) 501-2450 or ESchoen@CassavaSciences.com

FAQ

What is the date and time of Cassava Sciences' presentation at the 2023 H.C. Wainwright BioConnect Investor Conference?

Cassava Sciences' presentation will be on May 2nd, 2023, at 3 PM Eastern time.

Where can I watch the live webcast for the Cassava Sciences presentation?

You can watch the live webcast of Cassava Sciences' presentation at the conference here.

Is there an option to view an archived replay of Cassava Sciences' presentation?

Yes, the archived replay of the presentation can be accessed here.

Who is presenting for Cassava Sciences at the conference?

Remi Barbier, President & CEO of Cassava Sciences, will be presenting at the conference.

What is the focus of Cassava Sciences as a biotechnology company?

Cassava Sciences is focused on developing treatments for neurodegenerative diseases, specifically Alzheimer’s disease.